A NKp80-Based Identification Strategy Reveals that CD56 neg NK Cells Are Not Completely Dysfunctional in Health and Disease.

Fecha de publicación: 24/07/2020 Fecha Ahead of Print: 20/06/2020

Autores de IIS La Fe

María Tasias Pitarch

Autor

Participantes ajenos a IIS La Fe

Orrantia A
Terrén I
Izquierdo-Lafuente A
Alonso-Cabrera JA
Sandá V
Vitallé J
Moreno S
Uranga A
González C
Mateos JJ
García-Ruiz JC
Zenarruzabeitia O
Borrego F

Grupos

Investigacion clínica en enfermedades crónicas e Infección por el VIH

Investigador establecido

Marta Montero Alonso

Abstract

Natural killer (NK) cells are usually identified by the absence of other lineage markers, due to the lack of cell-surface-specific receptors. CD56 neg NK cells, classically identified as CD56 neg CD16+, are very scarce in the peripheral blood of healthy people but they expand in some pathological conditions. However, studies on CD56 neg NK cells had revealed different results regarding the phenotype and functionality. This could be due to, among others, the unstable expression of CD16, which hinders CD56 neg NK cells' proper identification. Hence, we aim to determine an alternative surface marker to CD16 to better identify CD56 neg NK cells. We have found that NKp80 is superior to CD16. Furthermore, we found differences between the functionality of CD56 neg NKp80+ and CD56 neg CD16+, suggesting that the effector functions of CD56 neg NK cells are not as diminished as previously thought. We proposed NKp80 as a noteworthy marker to identify and accurately re-characterize human CD56 neg NK cells.

Datos de la publicación

ISSN/ISSNe:: 2589-0042, 2589-0042
Tipo:: Article
Páginas:: 101298-101298
DOI:: 10.1016/j.isci.2020.101298
Factor de Impacto:: 1,805 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Orrantia A:: Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo 48903, Spain
Terrén I:: Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo 48903, Spain
Izquierdo-Lafuente A:: Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo 48903, Spain
Alonso-Cabrera JA:: Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo 48903, Spain
Sandá V:: Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo 48903, Spain
Vitallé J:: Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo 48903, Spain
Moreno S:: Ramón y Cajal Health Research Institute (IRYCIS), Ramón y Cajal University Hospital, Madrid 28034, Spain
Tasias M:: Hospital Universitari i Politecnic La Fe, Valencia 46026, Spain
Uranga A:: Biodonostia Health Research Institute, Donostia University Hospital, Donostia-San Sebastián 20014, Spain
González C:: Biodonostia Health Research Institute, Donostia University Hospital, Donostia-San Sebastián 20014, Spain
Mateos JJ:: Biocruces Bizkaia Health Research Institute, Hematological Cancer Group, Cruces University Hospital, Barakaldo 48903, Spain
García-Ruiz JC:: Biocruces Bizkaia Health Research Institute, Hematological Cancer Group, Cruces University Hospital, Barakaldo 48903, Spain
Zenarruzabeitia O:: Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo 48903, Spain
Borrego F:: Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo 48903, Spain

Ikerbasque, Basque Foundation for Science, Bilbao 48013, Spain